Early preclinical ADC studies showed highly potent payloads could induce severe on-target, off-tumor toxicity in normal LGR5-expressing tissues despite anti-tumor efficacy, establishing that therapeutic index is critical. The gene discussed is LGR5; the disease is neoplasm.